Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of initial clinical data from the FORTRESS ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...

Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation. Yet many patients ...

Head and neck cancer (HNC) represents a significant global health challenge, characterized by aggressive local invasion, frequent recurrence, and poor survival rates. Beyond its physical burden, HNC ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...

aThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA bPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA cIcahn Genomics ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a game plan, and coordinate their defenses in lymphoid organs. Researchers have ...